I bereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope CH CENTER 1600/290L Patent Application 09/761,995 MAY 0 2 2003 (Signature of person mailing) A. David Joran (Reg. No. 37,858) (Typed or printed name of person) PATENT AND TRADEMARK OFFICE YV JN RE APPLICATION: **©** E53GCA **Chen, Yuhpyng** L. ⊤3C-Examiner: Truong, T. N. APPLICATION NO.: 09/761,995 ATENT DEPARTMENT (15./03/49) Group Art Unit: 1624 FILING DATE: 01/17/2001 PETER INC LAZNO STRE IT TITLE: CORTICOTROPIN RELEASING 4 1

Commissioner for Patents Washington, D.C. 20231

tolling to dellarable of the homellland

FACTOR ANTAGONISTS

Sir:

<u>AMENDMENT</u>

This amendment is submitted in response to the Action issued January 29, 2003 in connection with the above-identified application. A response is due April 29, 2003. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows.

IN THE CLAIMS (clean copy)

1.(TWICE AMENDED) \(\rightarrow\) compound of the formula

R₃
R₄
R₅

الماري

or a pharmaceutically acceptable salt thereof, wherein

A is -CR₇;

 $B \ is \ -NR_1R_2, \ -CR_1R_2R_{11}, \ -C(=CR_2R_{12})R_1, \ -NHCHR_1R_2, \ -OCHR_1R_2, \ -SCHR_1R_2, \ -CHR_2OR_1, \ -CHR_1OR_2, \ -CHR_2SR_1, \ -C(S)R_2, \ -C(O)R_2, \ -CHR_2NR_1R_2, \ -CHR_1NHR_2, \ -CHR_1N(CH_3)R_2, \ or \ -NR_{12}NR_1R_2;$

Z is NH, O, S, -N(C₁-C₂ alkyl), -NC(O)CF₃, or - $C(R_{13}R_{14})$, wherein R_{13} and R_{14} are each,